Form 483

Inopak Ltd Form 483, 2017-03-24

FDA issued a Form 483 to Inopak Ltd on 2017-03-24 with 8 public-safe observations.

483· Form 483 issuedHuman Drugs8 observations

Inopak Ltd · Ringwood, United States · Issued March 24, 2017

Overview

  • 8 public-safe observations are available for this inspection.
  • 8 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

24 Mar 2017
21 CFR 211.110(a)

Control procedures to monitor and validate performance

Cited by Nancy F Scheraga

24 Mar 2017
21 CFR 211.165(e)

Test methods

Cited by Nancy F Scheraga

24 Mar 2017
21 CFR 211.166(a)

Lack of written stability program

Cited by Nancy F Scheraga

24 Mar 2017
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Nancy F Scheraga

24 Mar 2017
21 CFR 211.22(a)

Lack of quality control unit

Cited by Nancy F Scheraga

Inspected site

ILInopak LtdRingwood, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.110(a)Cited across public-safe Form 483 observations1x
21 CFR 211.165(e)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.22(a)Cited across public-safe Form 483 observations1x
21 CFR 211.25(a)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(1)Cited across public-safe Form 483 observations1x
FDCA 601(c)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 8 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere